EFFICACY OF DIFFERENT TOPICAL AMITRIPTYLINE CONCENTRATIONS IN THE TREATMENT OF PRIMARY BURNING MOUTH SYNDROME

Fatma Fathi Hussein, Lama Hussein El-Marssafy

DOI : 10.62610/RJOR.2025.2.17.24

ABSTRACT

Objectives: To compare and assess the efficacy of different amitriptyline (AMT) mouthrinse concentrations in the management of the primary burning mouth syndrome (PBMS) versus a placebo-controlled group. Subjects and methods: 60 patients with PBMS were divided into three groups, each of them involved 20 patients; Group I and Group II used AMT 10 mg and 25 mg tablets, respectively, while Group III used a placebo tablet dissolved in 100 ml distilled water as a mouthrinse for 2-3 minutes 3 times/day for 8 weeks. Severity of the pain was measured by the Numeric Pain Rating Scale (NPRS), and the Oral Health Impact Profile-14 (OHIP-14) scores were used to assess quality of life. Any adverse effects of the medication were recorded. Results: All participants experienced significant pain relief and improved quality of life. Intergroup comparison showed significant differences between groups I and II at 8 weeks in both scales (p-value < 0.01). Upon comparing groups I and II with group III, the mean NPRS scores decreased significantly at 2, 4, 6, and 8 weeks, as did the mean OHIP-14 scores at 8 weeks. Furthermore, a highly significant inverse correlation found between the AMT dose and the scores of both scales. All participants reported no adverse effects during this trial. Conclusion: AMT mouthrinse effectively relieves the pain linked to PBMS in a dose-dependent manner without causing any systemic or local side effects.